Korro Bio (NASDAQ:KRRO) Price Target Cut to $100.00 by Analysts at HC Wainwright

Korro Bio (NASDAQ:KRRO) had its price target cut by HC Wainwright from $115.00 to $100.00 in a research note released on Thursday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($2.17) EPS and FY2026 earnings at ($8.32) EPS.

Several other research firms also recently commented on KRRO. Cantor Fitzgerald raised shares of Korro Bio to a “strong-buy” rating in a report on Tuesday, April 29th. Oppenheimer started coverage on Korro Bio in a report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target for the company. Royal Bank of Canada decreased their price objective on Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 19th. Finally, Chardan Capital assumed coverage on Korro Bio in a research note on Wednesday, April 16th. They issued a “buy” rating and a $25.00 target price for the company. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $112.75.

Korro Bio Stock Up 1.0 %

KRRO opened at $15.56 on Thursday. Korro Bio has a twelve month low of $11.13 and a twelve month high of $98.00. The company’s 50-day moving average price is $17.78 and its two-hundred day moving average price is $34.32. The stock has a market cap of $146.12 million, a price-to-earnings ratio of -1.65 and a beta of 2.66.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.60) by $0.11. The firm had revenue of $2.55 million during the quarter, compared to analysts’ expectations of $0.13 million. As a group, sell-side analysts anticipate that Korro Bio will post -9.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in KRRO. KLP Kapitalforvaltning AS purchased a new stake in Korro Bio in the fourth quarter worth $53,000. AlphaQuest LLC grew its position in shares of Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock worth $83,000 after buying an additional 412 shares during the period. Wells Fargo & Company MN grew its position in shares of Korro Bio by 32.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock worth $129,000 after buying an additional 831 shares during the period. Deutsche Bank AG increased its stake in shares of Korro Bio by 29.4% in the 4th quarter. Deutsche Bank AG now owns 4,110 shares of the company’s stock worth $156,000 after acquiring an additional 935 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Korro Bio by 664.1% during the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock valued at $165,000 after acquiring an additional 3,759 shares during the period. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).